Dysplastic Nevus with Eruptive Melanocytic Lesions That Developed during Nilotinib Therapy for Chronic Myeloid Leukemia
نویسندگان
چکیده
منابع مشابه
Dysplastic Nevus with Eruptive Melanocytic Lesions That Developed during Nilotinib Therapy for Chronic Myeloid Leukemia
782 Ann Dermatol Received May 12, 2014, Revised February 16, 2015, Accepted for publication February 25, 2015 Corresponding author: Hyun Jeong Park, Department of Dermatology, Yeouido St. Mary’s Hospital, The Catholic University of Korea, College of Medicine, 10 63-ro, Yeongdeungpo-gu, Seoul 07345, Korea. Tel: 82-2-3779-1230, Fax: 82-2-783-7604, E-mail: [email protected] This is an Open Acc...
متن کاملSorafenib induced eruptive melanocytic lesions.
Sorafenib is a multikinase inhibitor FDA-approved for the treatment of advanced renal cell and hepatocellular carcinoma. Dermatologic side effects include hand-foot skin reaction, facial and scalp erythema and desquamation, splinter subungual hemorrhages, alopecia, pruritus, xerosis, keratoacanthomas, and squamous cell carcinomas. We report sudden eruption of melanocytic nevi diffusely in a pat...
متن کاملSuccessful Nilotinib Treatment in a Child with Chronic Myeloid Leukemia
A 16-year-old female was diagnosed incedentally with chronic myeloid leukemia (CML) in the chronic phase. She showed complete remission after 3 months of nilotinib treatment. CML is a rare malignant neoplasm in pediatric age. It is characterized by a Philadelphia chromosome, which comes from a genetic translocation between chromosomes 9 and 22. This translocation results in an abnormal fusion c...
متن کاملExtramedullary sudden blast crisis in chronic-phase chronic myeloid leukemia during first-line treatment with nilotinib
The natural course of chronic myelogenous leukemia (CML) has changed dramatically since the introduction of tyrosine kinase inhibitors (TKIs) with 490% of the patients achieving long-term disease control. Development of resistance with progression to accelerated phase/blastic crisis (AP/BC) is observed in a limited percentage of patients and is mainly documented in those who do not respond ‘opt...
متن کاملNilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib
Chronic myeloid leukemia (CML) is the consequence of a single balanced translocation that produces the BCR-ABL fusion oncogene which is detectable in over 90% of patients at presentation. The BCR-ABL inhibitor imatinib mesylate (IM) has improved survival in all phases of CML and is the standard of care for newly diagnosed patients in chronic phase. Despite the very significant therapeutic benef...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Dermatology
سال: 2015
ISSN: 1013-9087,2005-3894
DOI: 10.5021/ad.2015.27.6.782